TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intradialytic Drug Removal by Short-daily Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* currently receiving short-daily HD six times per week~* have no other acute intercurrent illness~Exclusion Criteria:~* history of a vancomycin, gentamicin or levofloxacin allergy~* weight within ± 30% of their ideal body weight~* Hgb \< 10 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous antibiotics (Type: EXPERIMENTAL): Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aged Garlic Extract on Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Age 40-65 years~* Framingham risk score 6-20%, and at least 2 components of the metabolic syndrome as defined by ATP III Clinical Identification of the Metabolic Syndrome (including impaired fasting glucose \> 110 mg/dl, treated hypertension or SBP \> 130 or DBP \> 85 mm Hg, plasma triglycerides \> 150 mg/dl, HDL cholesterol \< 35 mg/dl for men or \< 40 mg/dl for women, abdominal obesity as defined as waist \> 40 in for men, \> 35 in for women)~* Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them~* Subjects should be stable on their concomitant medications for at least 26 weeks prior to randomization~* Calcium Score \> 20 at baseline~* Subjects who agree to refrain from other anti-glycemic agent Exclusion Criteria~* A contraindication to AGE including: known hypersensitivity to drug.~* Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study~* Weight in excess of 300 pounds~* Bleeding disorder~* History of known coronary artery disease, myocardial infarction, stroke or life-threatening arrhythmia within the prior six months~* NYHA Class II- IV heart failure~* History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy~* Serum creatinine \> 1.4 mg/dl~* Diabetes Mellitus~* Triglycerides \> 400 at visit 1~* Drug or alcohol abuse, or current intake of more than 14 standard drinks per week~* Concurrent enrollment in another placebo-controlled trial~* Partial ileal bypass or known gastrointestinal disease limiting drug absorption~* Current diabetes or intake of anti-diabetic or other prohibited drug~* Current tobacco use~* Current use of anticoagulants (except for anti-platelet agents)~* Renal failure~* History of hypertensive encephalopathy or cerebrovascular accident~* Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sugar pill (Type: PLACEBO_COMPARATOR): placebo
- Aged Garlic Extract (Type: ACTIVE_COMPARATOR): 2400 mg of aged garlic extract

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Standard PET/CT vs. Digital PET/CT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ≥ 18 years old at the time of the scan~* Patient provides written informed consent~* Patient is referred for standard (F18 FDG; F18 NaF; Ga68 DOTATATE) or research (68Ga PSMA or 68Ga RM2) PET/CT~* Patient is capable of complying with study procedures~* Patient is able to remain still for duration of imaging procedure (approximately 60 minutes total for both PET/CT)~Exclusion Criteria:~* Patient is pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients undergoing digital PET/CT (Type: OTHER): Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, non-smoking pregnant women~* Ages 18-35~* Score of 28 or higher on the Predictive Index of Postnatal Depression~* Low to normal obstetric risk~* Before 34 weeks gestation~Exclusion Criteria:~* High Risk pregnancy~* Taking medications that affect the cardiovascular system (α blockers, β blockers, corticosteroids~* Chronic-use asthma medications (e.g. beta2-adrenoceptor agonists)~* Smoking during pregnancy~* Illicit drug/alcohol use during pregnancy~* Taking any psychotropic medications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Behavioral Intervention for PPD (Type: EXPERIMENTAL): Behavioral Intervention for PPD delivered over 3 in-person sessions.
- Treatment As Usual (Type: NO_INTERVENTION): Referred to Treatment in the Community.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Basic and Social Cognition in Veterans With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be diagnosed with Schizophrenia, Schizoaffective Disorder, or Psychosis not otherwise specified according to Diagnosis and Statistical Manual-IV criteria.~* In addition, the subjects will meet the following criteria:~  * Between 18 and 60 years of age~ * Estimated premorbid intelligence quotient \> 70 (based on reading ability)~ * Understand spoken English sufficiently to comprehend testing procedures~ * Clinically stable (e.g., no inpatient hospitalization in the 8 weeks prior to enrollment, no significant changes in medication in the 6 weeks prior to enrollment, and none anticipated for the 3 months of participation)~Exclusion Criteria:~* No clinically significant neurological disease as determined by medical history~* No history of serious head injury (e.g., loss of consciousness longer than 1 hour)~* No physical, cognitive, or language impairment of such severity as to adversely affect the validity of data~* No evidence of drug or alcohol dependence in the past six months, and not intoxicated at time of testing~* The patients psychotic experiences can be explained solely by the use of drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive Remediation (Type: ACTIVE_COMPARATOR): cognitive remediation
- Social Cognitive Skills Training (Type: EXPERIMENTAL): social cognitive skills training
- Hybrid Intervention (Type: ACTIVE_COMPARATOR): combined social cognitive and cognitive remediation training
- Skills Training (Type: OTHER): control training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Women presenting to Maternal Evaluation Unit at UAB hospital~2. Confirmed live intrauterine pregnancy (previous ultrasound, bedside ultrasound, fetal monitoring)~3. Complaint of headache~4. Minimal pain level of 4 on VRS~Exclusion criteria:~1. Systolic BP \>= 140 or diastolic BP\>=90 with 1+ protein on urine dip~2. Systolic BP \>=160 or diastolic BP\>=105~3. Focal neurological symptoms~4. Altered level of consciousness defined as not being oriented to person, place, situation, and/or year~5. Complaint of seizure~6. Known under lying brain abnormality~7. Fever~8. Use of \>3 grams of acetaminophen in past 24hrs~9. ONB in the past 3 months~10. Reported allergy to study medications (Bupivacaine, acetaminophen, or caffeine)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Occipital Nerve block (Type: EXPERIMENTAL): 1. Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.~2. Site of injection will be cleaned with an alcohol swab.~3. 5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.~4. After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved.
- Oral Acetaminophen/Caffeine Group (Type: ACTIVE_COMPARATOR): Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin Therapy in Women With Polycystic Ovary Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PCO - ESHRE/ASRM criteria: oligomenorrhea (\<8 spontaneous menses per year) and hyperandrogenism (hirsutism or acne) or hyperandrogenemia (testosterone \>70ng/dl)~* Normal prolactin, TSH, 17-OH progesterone~* No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly~* Age 18-40~* Reliable use of birth control pill for at least 3 months and no plans of pregnancy~Exclusion Criteria:~* Elevated creatinine kinase above 2 times upper limit of normal or liver enzymes (transaminases) above 2 times of upper limit of normal~* Use of any of the following medications: cyclosporine, fibrates, niacin, antifungal agents, macrolide antibiotics.~* Use of oral contraceptives and other steroid hormones 3 months prior to the study~* Contraindications to oral contraceptives

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3127760 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy males or females as determined by medical history and physical examination~* Male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product~* Female participants not of child-bearing potential~* Have a body mass index of 18.5 to 32 kilograms per square meter (kg/m\^2) inclusive~* Are normotensive (defined as supine systolic blood pressure \[BP\] less than 140 millimeters of mercury \[mm Hg\] and diastolic BP less than 90 mm Hg) without use of any antihypertensives~Exclusion Criteria:~* Have known allergies to LY3127760, related compounds or any components of the formulation, celecoxib or sulfonamides, or history of significant atopy. Participants with known aspirin allergy or allergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) should also be excluded~* Have any current or prior history of a significant gastrointestinal illness such as peptic ulcer disease, gastrointestinal (GI) bleeding, chronic gastritis, inflammatory bowel disease or chronic diarrhea~* Have evidence of other chronic liver disease, including but not limited to chronic alcoholic disease, nonalcoholic steatohepatitis, recent history (within 3 months of screening) of acute viral hepatitis or chronic autoimmune hepatitis~* Have used any NSAIDs, celecoxib, aspirin or acetaminophen (at doses greater than 1 gram per day), anticoagulants or antiplatelet agents within 14 days of admission~Part 2 and Part 3 only~* Have 1 plus pretrial pitting edema or 2 plus ankle or pedal edema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY3127760 (Single) (Type: EXPERIMENTAL): Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
- Placebo (Single) (Type: PLACEBO_COMPARATOR): Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
- LY3127760 (Multiple) (Type: EXPERIMENTAL): Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
- Placebo (Multiple) (Type: PLACEBO_COMPARATOR): Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
- Celecoxib (Multiple) (Type: ACTIVE_COMPARATOR): Multiple oral doses of 400 mg celecoxib administered QD for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically-confirmed, advanced unresectable solid tumors who have progressed within three months before screening/baseline visit Only patients who have confirmed PIK3CA status (wild type, mutation or amplification) will be allowed for screening (patients participating in the combination arm must be eligible for treatment with fulvestrant)~* Availability of a representative formalin fixed paraffin embedded tumor tissue sample~* At least one measurable or non-measurable lesion~* Age ≥ 18 years~* World Health Organization (WHO) Performance Status ≤ 2~* Good organ (hepatic, kidney, BM) function at screening/baseline visit~Exclusion Criteria:~* Brain metastasis unless treated and free of signs/symptoms attributable to brain metastasis in the absence of corticosteroid therapy (anti-epileptic therapy is allowed).~* Prior treatment with PI3K, AKT or mTOR inhibitor and failure to benefit~* Patient with peripheral neuropathy NCI-CTC Grade ≥ 3~* Patient with diarrhea NCI-CTC Grade ≥ 2~* Patient with acute or chronic pancreatitis~* Impaired cardiac function or clinically significant cardiac disease incl. unstable angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug.~* Patients with clinically manifest diabetes mellitus, history of gestational diabetes mellitus or documented steroid-induced diabetes mellitus~* Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BYL719 (Type: EXPERIMENTAL): In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
- BYL719 + fulvestrant (Type: EXPERIMENTAL): In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery.~Exclusion Criteria:~* All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice Clinical Classification of Pulmonary Hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Riociguat (Adempas, BAY63-2521)_individual dose titration (Type: EXPERIMENTAL): Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV infection~Exclusion Criteria:~* cancer severe jaundice pulmonary and renal chronic diseases prostatic diseases autoimmune diseases diabetes mellitus decompensated cirrhosis pregnancy hemoglobinopathies hemocromatosis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Silybin - vitamin E - phospholipids complex (Type: ACTIVE_COMPARATOR): Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
- placebo (Type: PLACEBO_COMPARATOR): sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II, aged between 20 and 70 years~* scheduled for elective laparoscopic cholecystectomy under general anesthesia with endotracheal intubation~Exclusion Criteria:~* recent respiratory tract infection or sore throat~* who were using analgesics or steroid preoperatively~* who have risk factors for oral cavity infection~* the surgical duration \< 60 minutes or \> 300 minutes

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Study Arms:
- triamcinolone (Type: ACTIVE_COMPARATOR): None
- chlorhexidine (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 4 - \<12 years (at the time of inclusion)~* Positive SPT~* Positive EAST~* Positive CPT~Exclusion Criteria:~* Serious chronic diseases~* Other perennial allergies

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Immunotherapy (Type: EXPERIMENTAL): Grass pollen allergens in a water/glycerol solution
- Placebo (Type: PLACEBO_COMPARATOR): Water/glycerol solution with phosphate buffered saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete